GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.
GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialise an antibody-drug conjugate (ADC) from Syndivia targeting metastatic castration-resistant prostate cancer.
- The agreement is worth up to £268 million.
- The therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.
GSK's push to broaden its oncology pipeline.
Author's summary: GSK acquires rights to Syndivia's ADC asset.